Murray L Barclay
Overview
Explore the profile of Murray L Barclay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfeld K, Barclay M, McNeill R, Frampton C, Doogue M, Stamp L
J Rheumatol
. 2025 Jan;
PMID: 39814431
Objective: Despite effective treatment, gout is poorly managed. The aim of this study was to determine rates of serum urate (SU) testing and allopurinol dose adjustment in patients admitted to...
2.
Bayoumy A, Mulder C, Ansari A, Barclay M, Florin T, Kiszka-Kanowitz M, et al.
Indian J Gastroenterol
. 2024 Feb;
43(1):36-47.
PMID: 38383877
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that encompasses two major conditions: Crohn's disease (CD) and ulcerative colitis (UC). Historically, IBD has been primarily...
3.
Stamp L, Keating P, Frampton C, Barclay M, Fanning N, Millier M, et al.
J Rheumatol
. 2024 Jan;
51(3):242-249.
PMID: 38224989
Objectives: To determine the influence of patient characteristics and disease activity on adalimumab (ADA) concentrations; to assess the relationships between ADA concentrations, the presence of antidrug antibodies (ADAb), and disease...
4.
Barclay M, Stamp L
Aliment Pharmacol Ther
. 2023 Dec;
59(1):118-119.
PMID: 38085937
No abstract available.
5.
Keating P, Hock B, Smith S, Chin P, ODonnell J, Barclay M
Intern Med J
. 2023 Nov;
53(11):2123-2127.
PMID: 37997271
A review of laboratory results across New Zealand for therapeutic drug monitoring (TDM) of infliximab and adalimumab concentrations and antidrug antibodies (ADAs) over 4 years was completed. Of 6591 results,...
6.
Butler J, Frampton C, Moore G, Barclay M, Jardine D
Clin Auton Res
. 2023 Aug;
33(6):623-633.
PMID: 37598402
Purposes: Habitual coffee drinking is ubiquitous and generally considered to be safe despite its transient hypertensive effect. Our purpose was to determine the role of the sympathetic nervous system in...
7.
Wang M, Barclay M, Chin P, Doogue M
Intern Med J
. 2022 Dec;
53(6):917-922.
PMID: 36510392
Background: New Zealand went into lockdown March 2020 successfully eliminating the circulation of the coronavirus disease 2019 (COVID-19) virus. During lockdown there were reduced rates of respiratory infections and hospital...
8.
Kubovy J, Barclay M
N Z Med J
. 2022 Sep;
135(1562):48-55.
PMID: 36137766
Aim: To ascertain Helicobacter pylori (Hp) diagnosis trends and cost in a New Zealand cohort. Methods: All Hp tests within Canterbury between 2013-2018 were retrospectively reviewed, exclusive of histology. Overall...
9.
Crouwel F, Simsek M, van Doorn A, Mulder C, Buiter H, Barclay M, et al.
Inflamm Bowel Dis
. 2022 Sep;
29(6):1000-1004.
PMID: 36099056
No abstract available.
10.
Liu Z, Julsgaard M, Zhu X, Martin J, Barclay M, Cranswick N, et al.
J Crohns Colitis
. 2022 Jul;
16(12):1835-1844.
PMID: 35779236
Background And Aims: For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is...